Postexposure rabies prophylaxis completed in 1 week: preliminary study
- PMID: 19995217
- DOI: 10.1086/649211
Postexposure rabies prophylaxis completed in 1 week: preliminary study
Abstract
Background: Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.
Methods: We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.
Results: Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.
Conclusions: After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.
Similar articles
-
Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.Vaccine. 2006 May 8;24(19):4116-21. doi: 10.1016/j.vaccine.2006.02.036. Epub 2006 Feb 28. Vaccine. 2006. PMID: 16545510 Clinical Trial.
-
Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.Vaccine. 2013 Mar 25;31(13):1748-51. doi: 10.1016/j.vaccine.2013.01.035. Epub 2013 Jan 29. Vaccine. 2013. PMID: 23370149 Clinical Trial.
-
Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis.Expert Rev Vaccines. 2014 Dec;13(12):1593-601. doi: 10.1586/14760584.2014.971764. Epub 2014 Oct 15. Expert Rev Vaccines. 2014. PMID: 25315021
-
Postexposure prophylaxis for rabies in resource-limited/poor countries.Adv Virus Res. 2011;79:291-307. doi: 10.1016/B978-0-12-387040-7.00013-5. Adv Virus Res. 2011. PMID: 21601051 Review.
-
Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.Travel Med Infect Dis. 2007 Nov;5(6):327-48. doi: 10.1016/j.tmaid.2007.07.004. Epub 2007 Sep 17. Travel Med Infect Dis. 2007. PMID: 17983973 Review.
Cited by
-
Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil.PLoS Negl Trop Dis. 2016 Sep 21;10(9):e0004920. doi: 10.1371/journal.pntd.0004920. eCollection 2016 Sep. PLoS Negl Trop Dis. 2016. PMID: 27653947 Free PMC article.
-
Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.Hum Vaccin Immunother. 2015;11(7):1748-53. doi: 10.1080/21645515.2015.1048938. Hum Vaccin Immunother. 2015. PMID: 26083005 Free PMC article. Clinical Trial.
-
Human rabies in Côte d'Ivoire 2014-2016: Results following reinforcements to rabies surveillance.PLoS Negl Trop Dis. 2018 Sep 6;12(9):e0006649. doi: 10.1371/journal.pntd.0006649. eCollection 2018 Sep. PLoS Negl Trop Dis. 2018. PMID: 30188890 Free PMC article.
-
Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.Hum Vaccin Immunother. 2014;10(1):114-9. doi: 10.4161/hv.26264. Epub 2013 Sep 5. Hum Vaccin Immunother. 2014. PMID: 24008819 Free PMC article. Clinical Trial.
-
Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.Hum Vaccin Immunother. 2021 Nov 2;17(11):4239-4245. doi: 10.1080/21645515.2021.1957413. Epub 2021 Sep 9. Hum Vaccin Immunother. 2021. PMID: 34499574 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous